Expert Webinar Highlights & Live Discussion ARA & DHA Supplementation in Extremely Preterm Infants

14 April – Expert Webinar Highlights & Live Discussion
ARA & DHA Supplementation in Extremely Preterm Infants
Scientific Evidence and Clinical Experiences of NeoMega36®

Educational Event by Neobiomics

We are pleased to introduce our new Expert Webinar Highlights & Live Discussion series and invite you and your colleagues to join the first session, focusing on ARA and DHA supplementation in extremely preterm infants.

This session will review key clinical studies and findings through curated pre-recorded expert presentations, followed by interactive discussion and live Q&A moderated by Dr. Stefan Johansson.

Date: 14 April 2026
Time: 15:30 – 16:10 CET
Location: Online (Teams Platform)

What to expect

• Presentation of data from the Mega Donna Mega trial and associated substudies, forming the scientific basis for NeoMega36®.
• Overview of NeoMega36®, an enteral lipid supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA), designed to support normal visual development in extremely preterm infants.
• Moderated discussion and audience Q&A, enabling participants to explore clinical implications and practical applications.

Agenda

15:30 – Welcome - Dr. Stefan Johansson
15:35 – Introduction to NeoMega36® – Dr. Stefan Johansson
15:40 – Mega Donna Mega trial and substudies – Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomised Clinical Trial
Prof. Ann Hellström, Professor of Pediatric Ophthalmology, Sahlgrenska University Hospital, Gothenburg, Sweden (pre-recorded presentation)
15:55 – Live discussion and audience Q&A
16:10 – Closing remarks - Dr. Stefan Johansson

This session is intended for healthcare professionals seeking to examine current evidence on ARA and DHA supplementation in extremely preterm infants and to discuss practical considerations in clinical care.

Registration is limited to ensure an interactive experience. Reserve your place today.

⁠Register Here

We look forward to your participation.

Best regards,
The Neobiomics Team